Early Relapse after Ciltacabtagene Autoleucel in High-Risk Multiple Myeloma: Implications for Risk-Adapted Therapy and Clinical Trial Design

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Doris K. Hansen, Lauren Cole Peres, Danai Dima, Saurabh Zanwar, Omar Alexis Castaneda Puglianini, Alicia C. Richards, Mahmoud Gaballa, Oren Pasvolsky, Aimaz Afrough, Brett Reid, Ariel Felipe Grajales-Cruz, Zhuoer Xie
+52 more Utkarsh Goel, Aishwarya Sannareddy, Christen M. Dillard, Christopher James Ferreri, Shebli Atrash, Cindy Varga, Andrew Jay Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Nilesh M. Kalariya, Damian Mikulski, Charlotte Burton Wagner, Christopher Ryan Cahoon, Peter K.C. Cheng, Christian A. Gordillo, Eli Zolotov, Jenny Bhurtel, Jeries Kort, Raffaella Cassano Cassano, Shonali Midha, James Davis, Rebecca M. Gonzalez, Megan Herr, Hamza Hassan, Sneha Purvey, Marcus Johannes Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Rahul Kumar Banerjee, Leyla Osman Shune, Ran Reshef, Kenneth H Shain, Melissa Alsina, Rachid C Baz, Douglas W. Sborov, Peter Michael Voorhees, Larry D. Anderson, Luciano J. Costa, Noa Biran, Shaji Kumar, Frederick Lundry Locke, Yi Lin, Surbhi Sidana, Krina K. Patel
DOI: 10.1016/j.jtct.2025.12.595
Cited by: 0

Fields of Study & Subjects

Multiple Myeloma Research and Treatments CAR-T cell therapy research Multiple Sclerosis Research Studies

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S414–S415
Publication date
1 February 2026
Language
EN